Skip to main content
. Author manuscript; available in PMC: 2016 Nov 4.
Published in final edited form as: Breast Cancer Res Treat. 2015 Nov 4;154(2):351–357. doi: 10.1007/s10549-015-3616-8

Table 4.

Summary of more frequent treatment-emergent adverse events occurring in at least 10 % of the patients in the safety population

PT n (%) PTX (n = 46) PWI (n = 46) PTI (n = 48)



All grades Grade 3–4 All grades Grade 3–4 All grades Grade 3–4
Any TEAE 43 (94 %) 5 (11 %) 45 (98 %) 5 (11 %) 47 (98 %) 16 (33 %)
Nasopharyngitis 8 (17 %) 0 7 (15 %) 0 6 (13 %) 0
Neutropenia 2 (4 %) 2 (4 %) 3 (7 %) 0 5 (10 %) 5 (10 %)
Peripheral sensory neuropathy 13 (28 %) 0 10 (22 %) 0 14 (29 %) 0
Paresthesia 8 (17 %) 0 5 (11 %) 0 4 (8 %) 0
Conjunctivitis 3 (7 %) 0 2 (4 %) 0 5 (10 %)
Vertigo 1 (2 %) 0 0 0 5 (10 %) 0
Diarrhea 8 (17 %) 0 18 (39 %) 1 (2 %) 14 (29 %) 0
Nausea 4 (9 %) 0 7 (15 %) 0 11 (23 %) 0
Stomatitis 4 (9 %) 0 6 (13 %) 0 8 (17 %) 0
Constipation 5 (11 %) 0 7 (15 %) 0 5 (10 %) 0
Alopecia 34 (74 %) NA 28 (61 %) NA 33 (69 %) NA
Rash 7 (15 %) 0 3 (7 %) 0 6 (13 %) 0
Myalgia 6 (13 %) 0 5 (11 %) 0 3 (6 %) 0
Arthralgia 6 (13 %) 0 5 (11 %) 0 1 (2.1 %) 0
Asthenia 26 (57 %) 0 21 (46 %) 0 24 (50 %) 0
Fatigue 8 (17 %) 0 6 (13 %) 0 6 (13 %) 0
Peripheral edema 4 (9 %) 0 1 (2 %) 0 5 (10 %) 0

Only rows with frequency of at least 5 % in at least one column are shown